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AbstrACt
Objectives In urological cancers, sex disparity exists for 
survival, with women doing worse than men. Suboptimal 
evaluation of presenting symptoms may contribute.
Design We performed a systematic review examining 
factors affecting the quality of the diagnostic process of 
patients presenting with symptoms of bladder or kidney 
cancer.
Data sources We searched Medline, Embase and the 
Cochrane Library from 1 January 2000 to 13 June 2019.
Eligible criteria We focused on one of the six domains of 
quality of healthcare: timeliness, and examined the quality 
of the diagnostic process more broadly, by assessing 
whether guideline-concordant history, examination, 
tests and referrals were performed. Studies describing 
the factors that affect the timeliness or quality of the 
assessment of urinary tract infections, haematuria and 
lower urinary tract symptoms in the context of bladder or 
kidney cancer, were included.
Data extraction and synthesis Data extraction and 
quality assessment were independently performed by two 
authors. Due to the heterogeneity of study design and 
outcomes, the results could not be pooled. A narrative 
synthesis was performed.
results 28 studies met review criteria, representing 583 
636 people from 9 high-income countries. Studies were 
based in primary care (n=8), specialty care (n=12), or 
both (n=8). Up to two-thirds of patients with haematuria 
received no further evaluation in the 6 months after their 
initial visit. Urinary tract infections, nephrolithiasis and 
benign prostatic conditions before cancer diagnosis were 
associated with diagnostic delay. Women were more likely 
to experience diagnostic delay than men. Patients who 
first saw a urologist were less likely to experience delayed 
evaluation and cancer diagnosis.
Conclusions Women, and patients with non-cancerous 
urological diagnoses just prior to their cancer diagnosis, 
were more likely to experience lower quality diagnostic 
processes. Risk prediction tools, and improving guideline 
ambiguity, may improve outcomes and reduce sex 
disparity in survival for these cancers.
IntrODuCtIOn
Making a correct and timely diagnosis is para-
mount for patient safety and high quality 
healthcare. The US National Academy 
Sciences, Engineering and Medicine 
(NASEM—formerly the Institute of Medi-
cine) report ‘Improving Diagnosis in Health 
Care highlights the importance of research 
on reducing missed and delayed diagnosis 
and targeting contributory factors that lead 
to diagnostic errors.1 Cancer is one of the 
most common conditions to be affected by 
diagnostic errors2 and outpatient malpractice 
claims.3 This, in addition to the compelling 
rationale for early detection, makes cancer 
an excellent disease model for examining 
diagnostic safety. Bladder and kidney cancer, 
two relatively common cancers, pose partic-
ular diagnostic challenges. Uniquely among 
common cancers, women with bladder 
cancer have poorer survival than men with 
the same cancer.4 Missed or delayed referral 
and diagnosis may contribute to the survival 
difference between men and women with 
these urological cancers.5
Timeliness, one of the six domains of 
healthcare quality described by the NASEM, 
can be regarded as the most relevant for 
evaluating the diagnostic process in cancer.1 
Timely diagnosis of cancer is important 
to optimise clinical outcomes and patient 
experience.6 7 In the UK, efforts to promote 
early diagnosis and reducing delays during 
the diagnostic process have informed many 
strengths and limitations of this study
 ► This is the first study to our knowledge that exam-
ined factors affecting the diagnostic quality of both 
kidney and bladder cancer.
 ► We examined all relevant symptoms in these pa-
tients, not limiting to haematuria only.
 ► We were unable to perform a meta-analysis due to 
the heterogeneity of the studies.
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initiatives aiming to improve outcomes for cancer 
patients.8
We performed a systematic review to examine the 
factors affecting the quality of the diagnostic process, in 
particular timeliness, for patients presenting with urolog-
ical symptoms that may be suggestive of kidney or bladder 
cancer. Our secondary aim was to examine existing defi-
nitions for timeliness of evaluation, referral and diagnosis 
for these patients.
MEthODs
search strategy and study inclusion
We searched Ovid Medline and Embase for relevant from 
1 January 2000 to 29 January 2018, with an updated search 
on 13 June 2019 of both databases and a new search of the 
Cochrane Library from inception to the same date. We 
did not restrict on publication type or languages (online 
supplementary appendix 1). We restricted our search to 
studies published from 2000 due to prior knowledge that 
there were few early relevant studies,9 and that the quality 
of the diagnostic process for cancer might have been 
affected by the introduction of national initiatives such as 
the fast-track referral pathways in the UK in 2000.
We focused on clinical features listed in the English 
2015 National Institute for Health and Care Excellence 
guidelines for suspected cancer10 in order to examine the 
population that are most likely to have cancer. We based 
our outcome measures of diagnostic timeliness on inter-
nationally accepted definitions of the diagnostic inter-
vals: for example, primary care interval=time from the 
patient’s first presentation to a primary care practitioner 
(PCP), to referral.11 12 We also examined the quality of 
the diagnostic process more broadly, by assessing whether 
appropriate or guideline-concordant history, examina-
tion, diagnostic tests and referrals were performed during 
the evaluation of symptoms.
All titles and abstracts were screened by YZ, with 10% 
of a random selection independently assessed by a 
second reviewer (MM). Both authors then independently 
assessed the full-text articles after screening of titles and 
abstracts. Consensus was sought from GL and FW where 
disagreements arose.
Inclusion criteria:
 ► Studies describing the factors that affect the timeliness 
or quality of the assessment of the following clinical 
features in the context or bladder or kidney cancer:
Urinary tract infections (UTIs).
Haematuria.
Lower urinary tract symptoms (including dysuria, 
urinary frequency, urgency, incontinence and 
nocturia).
Exclusion criteria:
 ► Studies only describing population or patients under 
the age of 18 years.
 ► Conference abstracts, correspondence, editorials, 
short reports and the grey literature.
 ► Case reports or case series of <10 patients.
Data extraction and quality assessment
YZ and MM independently performed data extraction, 
using a data collection template, on study characteristics, 
diagnostic intervals, frequency of evaluations, and the 
patient, clinician and system factors affecting the diag-
nostic intervals and frequency of evaluations. Quality 
appraisal was performed using a modified version of the 
critical appraisal skills programme checklist for cohort 
studies by both authors (table 1 footnote).13 Any disagree-
ments were resolved by discussion with all members of the 
research team.
Data synthesis and analysis
We were unable to pool the results due to the hetero-
geneity of the study design and outcomes. A narrative 
synthesis was therefore performed.
Patient and public involvement
No patient was involved in this review.
rEsults
study characteristics and quality
Twenty-eight papers, representing 583 636 people, were 
included after full-text reviews (figure 1). All studies were 
from high-income countries. These include 18 from the 
USA, two from Australia, two from the UK, two from 
Sweden and one each from Finland, Canada, Austria and 
Italy, and Germany and Austria (in one study). Six exam-
ined cancer patients with no predefined clinical features 
(five bladder, one both bladder and kidney), five focused 
on patients with haematuria (one of which included only 
visible haematuria (VH)), eight examined bladder cancer 
patients with haematuria and one focused on upper 
urothelial tract cancer patients with haematuria. Eight 
studies were carried out in the primary care setting, 12 in 
hospital and 8 in both (table 1).
The main bias and applicability concerns related to 
the suboptimal identification and/or adjustment for 
confounders in 18 of the studies, 6 of which were studies 
using questionnaires,14–19 10 were retrospective cohort 
studies providing descriptive statistics mainly, using 
record reviews (n=5)20–24 and electronic health records 
(n=5),25–29 1 was a case–control study30 and 1 an ecolog-
ical study.31
Quality of diagnostic process
Diagnostic timeliness
Seventeen of the 28 included studies described diagnostic 
intervals for patients with either urological symptoms or 
who had been diagnosed with bladder or kidney cancer 
(table 2).
Definitions of timely evaluation, referral and diagnosis, 
were described in 12 studies. For time to first evaluation 
including cystoscopy, upper urinary tract imaging or urine 
cytology, Garg et al used a threshold of 30 days,32 while 
two studies examined proportions of patients undergoing 
these tests within 6033 and 90 days.24 The remaining studies 
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Figure 1 PRISMA flow diagram.
used 180 days as time cut-offs for which they considered 
evaluation should be carried out,22 28 34–36 although one 
also looked at completion within 365 years, and beyond.28 
Thresholds for referral was set at 90 days by one paper,27 
while delays in cancer diagnosis were defined as greater 
than 90 days37 and in 3 month increments up to 1 year.26 28
Other quality dimensions
We found no standard definition for high quality care 
during the diagnostic process in any of the included 
studies. Most studies reported the frequency of appro-
priate or guideline-concordant diagnostic tests and refer-
rals performed during diagnostic evaluation (online 
supplementary appendix 2). Studies examining the 
frequency of non-evaluation of haematuria reported 
this to be 47%–81% within 60 days of initial symptom 
presentation,24 33 reducing to 36%–65% in studies by 
180 days.22 34–36
Eleven studies reported the percentages of investiga-
tions and referrals performed in patients with haema-
turia,18 21 22 24 25 28 33–36 38 seven of which also specified 
time-frames during which these evaluations should be 
completed22 24 28 33–36 (online supplementary appendix 2). 
Five studies reported that only 5%–25% of these patients 
received both imaging and cystoscopy (commonly defined 
as ‘complete evaluation’ by the studies) by 6 months of 
their first presentation with haematuria25 28 34–36 and case 
series of 100 patients in a single institution reported this 
percentage to be 64% in their cohort.22
Studies reported variations in the percentages of patients 
with haematuria who received urine culture (15%–84%), 
urine cytology (5%–43%), imaging tests (14%–76%) and 
cystoscopy (6%–26%) at at least 2 months after presenta-
tion, indicating that there were variations in how clinicians 
evaluate patients with haematuria. In studies that focused 
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on the type of haematuria, a larger proportion of patients 
with VH (25%)25 received both imaging and cystoscopy 
than patients with non-visible haematuria (NVH) (up 
to 14%).25 28 35 Between 21% and 36% of patients with 
haematuria received a urological referral,34 35 38 although 
a survey study from almost 800 PCPs in the USA reported 
that about one-third and two-thirds of them would refer 
patients with NVH and VH, respectively.18
One secondary care study reported non guideline-com-
pliant practice in over a third of postmenopausal women 
with asymptomatic haematuria, with no documentation 
of full genitourinary examination with vaginal tissue 
quality and presence of prolapse.21
Presenting symptoms
Ten of the 20 studies which extracted symptom infor-
mation used coded information from routine or claims 
data,21 25 28 29 31 34 35 37–39 5 used self-reported symptoms 
from questionnaire and audit data,14–16 19 40 6 studies 
performed direct record review22 24 25 30 33 41 and 1 used 
coded information and record review.17
Eleven studies examined the direct association between 
the type of presenting symptoms and quality of the 
diagnostic process, the majority focusing on haema-
turia18 19 22 24 27 28 30 39–41 and one on UTI.42 No other 
presenting symptoms were examined. A large popu-
lation-based study in the UK reported that bladder or 
kidney cancer patients presenting with haematuria were 
significantly less likely to have three or more consultations 
before a general practitioner (GP) referral compared with 
those who did not present with haematuria (OR 0.29 CI 
0.19 to 0.46, p<0.001 for bladder cancer; OR 0.64 CI 0.30 
to 1.37, p=0.25 for kidney cancer).40 An earlier study of 
about 1000 patients found that there was also a dose-de-
pendent relationship between the number of haematuria 
visits and the likelihood of a urological referral (HR 
5.18 and 7.66 for 2 and 3 visits, respectively, vs 1 visit, 
p<0.0001),27 and a high-quality US study involving claims 
review found that increasing number of haematuria visits 
was associated with diagnostic delay for bladder cancer 
patients.39
VH predicted a shorter time to evaluation,39 to referral,19 
a lower likelihood of incomplete evaluation,22 24 shorter 
time from GP referral to urology consultation,41 and a 
shorter time to diagnosis39 than NVH.
Other recent diagnoses preceding cancer diagnosis
Between 20% and 61% of women and 15% and 35% of 
symptomatic men were treated or diagnosed with a UTI 
before being diagnosed with bladder cancer.14 15 37 39 
Women are also four times as likely as men to receive 
three or more courses of treatments for UTIs before 
their cancer diagnosis (15.8% vs 3.8% for women vs men, 
p=0.04).15
In two case series, it was also reported that a signifi-
cant proportion of bladder cancer patients (up to 40%) 
received symptomatic treatments for either lower urinary 
tract symptoms or abdominal pain before referral to a 
urologist14 or were not further evaluated, with women 
more likely to be affected than men (41.7% vs 16.2% 
once or twice, 5.6% vs 2.9% three or more times, women 
vs men; p=0.04).15
Two large US studies reported that benign diagnosis 
(up to 12 months prior to cancer diagnosis) such as UTIs, 
nephrolithiasis and prostate-related diagnosis were asso-
ciated with delays in cancer diagnosis.37 39 UTIs were asso-
ciated with a twofold increase in the odds of diagnostic 
delay by at least 3 months in both sexes for both upper 
tract urothelial cancer and bladder cancer,37 39 compared 
with those with no UTI diagnosis prediagnosis (OR 1.97, 
CI 1.74 to 2.22).39 This was regardless of whether patients 
first presented to a urologist or other specialty doctors.37 
Nephrolithiasis (RR 1.29, CI 1.07 to 1.54; p=0.007 vs RR 
1.09, 0.81 to 1.47 for men vs women) and benign prostatic 
conditions (such as prostatitis, benign prostatic hyper-
plasia and benign prostatic nodule) were more likely to 
predict diagnostic delay in men than women with upper 
tract urothelial cancer.37 In this nationwide insurance 
claims study, no validation of coded information was 
performed using medical record review.
Patient factors
Sex
The effect of sex on diagnostic activity and timeliness were 
reported by 15 studies.14 15 19 22 25 27–29 31 32 34 36 38–40 Most 
evidence indicated that women were less likely than men 
to undergo any investigation,35 have complete evalua-
tion,28 35 be referred to a specialist27 29 41 and to have cystos-
copy or imaging.31 36 41 Female sex was also a consistent 
predictor for delayed evaluation of haematuria32 34 39 and 
UTIs,15 25 and longer diagnostic intervals for cancer.29 32 40 
This sex disparity with respect to evaluation and referral 
was insignificant for patients with NVH.22 25 38 One 
Finnish study using patient questionnaires reported no 
difference in patient (time from symptom recognition 
to presentation) and primary care (time from presenta-
tion to referral to a urologist) intervals in 131 low-grade 
bladder cancer patients between men and women.19
Other patient factors
In general, evidence for other patient factors affecting the 
quality of the diagnostic process was less consistent. Two 
large US studies consisting of over 65 000 patients in total 
found that older bladder cancer patients with haematuria 
had longer delays to evaluation than younger patients.26 32 
Increasing comorbidity predicted slower time to urolo-
gist, longer delay to evaluation,32 and diagnosis39 in two 
large US samples. While five of the six studies reported 
no association between ethnicity and quality of the diag-
nostic process, one study with about 1400 participants 
reported that African-American bladder cancer patients 
were less likely than their Caucasian counterparts to: be 
referred to a urologist (adjusted OR 0.72; 95% CI 0.56 to 
0.93; have a cystoscopy (adjusted OR 0.67; 95% CI 0.50 to 
0.89), or have imaging (adjusted OR 0.75; 95% CI 0.59 to 
0.95).34
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Table 3 Summary of association between patient factors and diagnostic safety and timeliness
Patient factor
No of studies 
exploring risk 
factor
Association between patient factor and diagnostic safety and timeliness
Delayed / incomplete 
evaluation Delayed referral
Longer diagnostic 
interval
Sex 15 Women>men Women>men Women>men
Increasing age 12 NS24 25 28 38
Positive association26 32
NS19 25 32 41 NS39
Ethnicity 7 NS25 26 28 32 35 36
African-American worse34
NS25 26 32 35 36
African-American worse34
NS25 26 32 35 36
SES 5 NS16 26 36 39 41
Comorbidity 4 Positive association32
NS24 37
  Positive association39
NS24 37
Smoking 6 NS25 35 36 41
Positive association38
NS19 25 35 36 41   
Anticoagulant 
use
5 NS24 35 41
More likely to receive imaging36
NS24 30 35 41 NS30
NS, statistically non-significant; SES, socioeconomic status.
The evidence between socioeconomic status, comor-
bidity, smoking and anticoagulant use was either non-sig-
nificant or weak (table 3).
Clinician factors
Physician type
Six studies from the USA examined the type of clinicians 
as a predictor for diagnostic delay (table 4). Patients who 
first saw a urologist for their symptoms were less likely 
to have a delay in evaluation32 or cancer diagnosis37 and 
more likely to have guideline-adherent evaluation22 than 
those who first saw another specialty doctor.
When comparing specialties excluding urology, a 
mixed pattern was seen with respect to referral and use 
of investigations. In general, there was little evidence 
to suggest that family physicians in the USA differ from 
other specialists with respect to evaluating haematuria. 
Family physicians may be less likely to refer for VH,25 27 
although evidence for delayed referral in patients with 
UTI and NVH was less clear.18 25
system factors
Diagnostic pathways
Three studies examined the impact of interventions in 
the diagnostic pathways on diagnostic intervals in the UK 
and Sweden.16 20 30 A single institution UK study found 
that the time from GP referral to first hospital visit short-
ened from 42.9 to 21.3 days (p<0.001) after the intro-
duction of the fast-track pathway, in which patients with 
alarm symptoms are typically seen or investigated by a 
specialist within 2 weeks of a GP referral.20 In Sweden, the 
introduction of a telephone hotline for patients with VH 
reduced the time from haematuria to urology referral 
(33 to 14 days, p=0.32), referral to diagnosis (19 to 8 days, 
p=0.003) and total healthcare interval (50 to 29 days, 
p=0.03).16 Patients with eligible symptoms were able 
to access a nurse consultant directly by telephone, who 
then scheduled the patient for serum creatinine, urine 
cytology and appointment with a urologist for flexible 
cystoscopy and CT urography within 2 weeks, all with the 
same priority as other patients referred by their GP but 
bypassing the routine referral system.16 Another Swedish 
study studying a similar streamlined diagnostic pathway 
found that it shortened the diagnostic interval from 35 
to 25 days (p=0.01) although time to treatment did not 
change from a regular referral pathway.30
Other factors
Other factors that were found to impact on the quality 
of the diagnostic process were described by studies using 
direct record review. These include patient factors such as 
not attending, cancelling or declining to attend follow-up 
appointments,33 delays in PCPs reviewing results, lack of 
receipt of referral,17 and scheduling and coordination 
delay of follow-up test or appointment,24 33 although the 
detailed effects of these factors on the quality of the diag-
nostic process were not reported.
DIsCussIOn
Our review identified several potential areas of missed 
opportunities in urological cancer diagnosis; it also 
provides evidence for informing the development of 
future interventions and research.
non-evaluation of haematuria
Studies reported high frequencies of non-evaluation 
of haematuria, with about two-thirds of patients having 
no evaluation up to 180 days after initial presentation. 
Although we found no consistent definition of diagnostic 
timeliness for evaluation, referral and diagnosis of urolog-
ical cancer, high percentages of non-evaluated cases likely 
harbour missed opportunities for a timely diagnosis. For 
instance, patients with VH should receive renal function 
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Table 4 Associations between physician specialty and quality of diagnostic process for patients presenting with different 
clinical features precancer diagnosis
Clinical feature Delay in evaluation Delay in referral Delay in diagnosis
Urinary tract infection 
(UTI)
No difference between PCP* and other 
specialists or ED physicians (Buteau)
No difference between PCP* and 
other specialists or ED physicians 
(Buteau)
Both urologist and non-urologist 
(urologist: RR1.74, CI 1.31 to 
2.31, p<0.001; non-urologist RR 
1.44, CI 1.22 to 1.71, p<0.001 
(Chappidi)
Microscopic 
haematuria
No difference between PCP* and other 
specialists or ED physicians (Buteau); OBGYN 
less likely to perform imaging than medical 
counterparts (p<0.004) (Neider); guideline 
concordant with urologist vs non-urologist (OR 
54.7, CI 10 to 102, p<0.0001) (Shinagare)
No difference between PCP* and 
other specialists or ED physicians 
(Buteau, Neider)
  
Macroscopic 
haematuria
OBGYN less likely to perform imaging than 
medical counterparts (p<0.01) (Neider)
PCP* less than other specialists 
or ED physicians (Buteau); no 
difference between specialties 
(Neider)
  
Haematuria (not 
specified)
Initial visit with urologist associated with 
reduced odds of delayed evaluation (OR 0.34, 
CI 0.31 to 0.68, p<0.001) compared with 
primary care and OBGYN (Garg)
Internal medicine providers and 
other specialists more likely than 
family physicians to refer (HR 
1.30, 1.03 to 1.64; HR 1.72, 1.01 
to 2.90). No difference in hospital 
specialists from family medicine 
(Johnson).
  
Nephrolithiasis     Delay in non-urologist versus 
urologist (RR 1.25, CI 1.05 to 1.49, 
p=0.01) (Chappidi)
Benign prostate 
conditions
    Delay in non-urologist versus 
urologist (new prostate 
conditions—RR 1.41, CI 1.12 to 
1.78, p=0.003); recurrent prostate 
conditions RR 1.94, CI 1.45 to 
2.58, p<0.001) (Chappidi)
*PCP includes family medicine and internal medicine.
ED, emergency department; OBGYN, obstetricians and gynaecologists; PCP, primary care physician.
testing, imaging and urology referral for cystoscopy once a 
transient cause such as UTI has been excluded.43 Patients 
with persistent NVH should additionally receive a blood 
pressure check and urinary albumin-creatinine ratio as 
part of the evaluation.43 Given that the PPV of haematuria 
for urological cancer can be as high as 11%,44 lack of eval-
uation could lead to missed diagnoses. Improving clini-
cians’ awareness and adherence to existing guidelines as 
well as using electronic algorithms to flag up abnormal 
findings33 may reduce such missed opportunities.23
Women experience poorer quality of diagnostic process than 
men
Our review found that women with haematuria were 
more likely to be treated for UTIs or for pain, and less 
likely to be evaluated further or referred than men. 
Benign conditions such as UTIs and atrophic vaginitis are 
commoner in women. At the same time, women are less 
likely to have bladder and kidney cancer than men (M:F 
ratio about 3:1 and 1.7:1 for bladder and kidney, respec-
tively).45 This may be due to differing exposure to lifestyle 
and environmental factors, and biological propensity to 
these cancers by sex.4 The combined effect of greater 
frequency of non-neoplastic disease in women, and the 
fact that urological cancer is less common in women, 
means that the PPV of relevant symptoms for bladder and 
kidney cancer is lower in women than men.
Although a relevant urological symptom is more likely 
to be due to a benign cause in women than in men, avoid-
able diagnostic delay for urological cancer may still occur 
if there is a failure to ensure the resolution of symptoms. 
Current American Urological Association guidelines 
on the evaluation of asymptomatic microscopic haema-
turia recommends repeat urinalysis after the treatment 
of other causes, and subsequent renal function testing, 
cystoscopy and imaging if symptoms do not resolve after 
treatment.46 However, the low diagnostic yield of NVH 
evaluation and the frequency of other benign causes 
(such as infection) in everyday clinical practice may affect 
guideline adherence, and contribute to diagnostic delay. 
Future research should examine risk stratification based 
not only on presence of symptoms, but also on their 
severity, chronicity, recurrence or persistent nature. For 
example, guidelines should address cut-offs for degree of 
NVH that should warrant active reviews after treatments 
for UTIs; or cut-offs for number of UTIs treated before 
referral), while also taking into account cost-effectiveness 
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of any follow-up actions. Emerging urine biomarkers 
and risk prediction tools may also be useful additions to 
improve diagnostic yield.47 48
Concomitant benign conditions
The challenge in clinical practice arises when a 
presenting symptom may be the result of concomi-
tant benign disease or cancer. In these cases, it is likely 
that a significant proportion of patients will be appro-
priately treated and reviewed, averting unnecessary 
investigations.
The observation that a UTI diagnosis delays cancer 
diagnosis in patients first seen by both urologists and 
non-urologists37 suggests that diagnostic reasoning is 
challenging for clinicians in such situations. The PPV 
of a symptom for cancer probably falls if the patient has 
concomitant diseases which cause the symptom. Some 
evidence suggests that conditions such as benign pros-
tate disease and kidney stones also delay the diagnosis 
of kidney cancer.37 Whether and how much of this diag-
nostic delay is avoidable is yet to be determined, and 
should be a priority for future research. While current 
UK guidelines recommend that patients with persistent 
or recurrent UTIs should be referred for further evalu-
ation, there is no US equivalent, nor guidelines on the 
management of other concomitant benign conditions 
and possible cancer. When no guideline exists, or adher-
ence is not possible, close follow-up to ensure improve-
ment or resolution of symptoms should take place, and 
patients should be instructed to return if symptoms do 
not improve.
Clinician and system factors
Patients experienced shorter diagnostic intervals if they 
first presented to a urologist instead of another specialty 
doctor. This is not surprising given that urologists are 
likely to have better access to investigations, typically 
consisting of cystoscopy and upper renal tract imaging. 
The variations seen in evaluation and referral between 
other clinical specialties may indicate different levels 
of guideline awareness and adherence, although this 
evidence is scarce and inconsistent.
Process or system delays, such as patient non-atten-
dance at appointments, delays in scheduling of appoint-
ments or non-receipt of referrals, all contribute to 
diagnostic delay,17 24 33 49 although the magnitude of 
their effects is unclear. In addition to improving process 
and workflow issues within primary and secondary care 
services, wider system changes such as providing direct 
access to imaging and streamlining referral processes 
may also play a role in expediting cancer diagnosis. 
Diagnostic pathways such as the fast-track referral system 
for patients with alarm symptoms in the UK, or a tele-
phone hotline service, may shorten primary care and 
total healthcare interval, although the cost-effectiveness 
of such pathways need to be evaluated in specific health 
system contexts.
strengths and limitations
Our review is the first to examine the evidence relating 
to factors affecting the quality of the diagnostic process 
in patients with bladder and kidney cancer. It builds on 
a previous review examining haematuria assessment in 
bladder cancer patients,9 and looks at a range of urolog-
ical symptoms, and also patients with kidney cancer. 
Although some of the studies did not adjust for all the 
confounders, the descriptive sections related mainly to 
the diagnostic intervals and appropriate statistical anal-
yses were performed for examining the factors affecting 
these intervals, where relevant.
Unfortunately, we were unable to perform a meta-anal-
ysis due to the heterogeneity in study designs and 
outcomes. We were also unable to check the veracity of 
the comorbid disease labels in the papers that used coded 
information. All the studies are from high-income coun-
tries, and therefore may be less generalisable to other 
countries with differing healthcare systems.
COnClusIOn
We found lack of consistency in defining diagnostic 
quality, including timeliness, of bladder and kidney 
cancer, and insufficient exploration of population-based 
evidence related to clinician and system factors affecting 
the quality of the diagnostic process. Our review high-
lights the need to improve evaluation of haematuria, 
and to develop high-quality evidence to inform guide-
lines on specific thresholds for active follow-up of high-
risk symptomatic patients, which could be incorporated 
into risk prediction tools and clinical decision support. 
Future research should also identify and target prevent-
able delays, especially in the context of concomitant 
benign conditions. Identifying patients with evaluation 
delays through electronic algorithms may also improve 
outcomes and reduce the sex inequality in survival for 
these cancers. In sum, our review identifies several poten-
tial areas of missed opportunities in bladder and kidney 
cancer diagnosis that may be avoidable and amenable to 
targeted interventions.
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